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Abstract
Aims
To compare full-length mechano growth factor (full-length MGF) with human recombinant
insulin-like growth factor-I (IGF-I) and human recombinant insulin (HI) in their ability to acti-
vate the human IGF-I receptor (IGF-IR), the human insulin receptor (IR-A) and the human
insulin receptor-B (IR-B), respectively. In addition, we tested the stimulatory activity of
human MGF and its stabilized analog Goldspink-MGF on the IGF-IR.
Methods
The effects of full-length MGF, IGF-I, human mechano growth factor (MGF), Goldspink-
MGF and HI were compared using kinase specific receptor activation (KIRA) bioassays
specific for IGF-I, IR-A or IR-B, respectively. These assays quantify activity by measuring
auto-phosphorylation of the receptor upon ligand binding.
Results
IGF-IR: At high equimolar concentrations maximal IGF-IR stimulating effects generated by
full-length MGF were similar to that of IGF-I (89-fold vs. 77-fold, respectively). However,
EC50 values of IGF-I and full-length MGF for the IGF-I receptor were 0.86 nmol/L (95% CI
0.69–1.07) and 7.83 nmol/L (95% CI: 4.87–12.58), respectively. No IGF-IR activation was
observed by humanMGF and Goldspink-MGF, respectively. IR-A/IR-B: At high equimolar
concentrations similar maximal IR-A stimulating effects were observed for full -length MGF
and HI, but maximal IR-B stimulation achieved by full -length MGF was stronger than that by
HI (292-fold vs. 98-fold). EC50 values of HI and full-length MGF for the IR-A were 1.13 nmol/
L (95% CI 0.69–1.84) and 73.11 nmol/L (42.87–124.69), respectively; for IR-B these values
were 1.28 nmol/L (95% CI 0.64–2.57) and 35.10 nmol/L (95% 17.52–70.33), respectively.
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Conclusions
Full-length MGF directly stimulates the IGF-IR. Despite a higher EC50 concentration, at
high equimolar concentrations full-length MGF showed a similar maximal potency to acti-
vate the IGF-IR as compared to IGF-I. Further research is needed to understand the actions
of full-length MGF in vivo and to define the physiological relevance of our in vitro findings.
Introduction
Insulin-like growth factor-I (IGF-I) is considered a key regulator of muscle development and
growth [1]. For skeletal muscle, IGF-I in conjunction with additional growth factors, coordi-
nates myoblast proliferation, differentiation, and fiber formation during normal growth as well
as during regeneration after injury [1]. The IGF-I gene spans more than 90 kb of chromosomal
DNA and generates three isoforms. Alternative splicing of IGF-I pre-mRNA can produce three
multiple mRNA species, depending on the inclusion of alternative leader and C-terminal exons
[2]. All mRNA splice variants contain exons 3 and 4, which encode the mature 70-amino-acid
IGF-I peptide consisting of the B, C, A, and D domains. All three mRNA splice variants encode
C-terminal extensions termed E-domains to denote their positions relative to the BCAD
domains of mature IGF-I: mRNAs containing exon 4 spliced to exon 6 are designated as
IGF-IEa, mRNAs containing exon 5 spliced to exon 4 have been designated as IGF-IEb,
whereas those containing exon 4 spliced to exon 5 and exon 6 are designated IGF-IEc in
humans (Fig 1)[2]. Due to the apparent role of IGF-IEc up-regulation in muscle remodeling,
IGF-IEc is also named mechano growth factor (MGF) [2, 3]. Rather than acting in an endo-
crine fashion, IGF-IEc produced in the body is more likely functioning in a paracrine/autocrine
mode [4]. For example, IGF-IEc produced in skeletal muscles in response to mechanical stimuli
or damage, functions in skeletal muscles probably as a local muscle growth/repair factor [5]. It
has been further suggested that after injury or training locally produced IGF-IEc in muscles is
required to activate muscle stem (satellite) cells to divide thereby providing extra nuclei neces-
sary for muscle repair and hypertrophy [5].
A single injection of MGF-cDNA containing plasmid vector (which corresponds to IGF-I
Ec in human) resulted in a 25% increase in the mean muscle fiber cross-sectional area of the
injected normal muscle within two weeks [4]. Consequently, IGF-IEc represents a potential
drug candidate for the treatment of several neuromuscular disorders. However, its potential
misuse as doping in sport games has been also identified and therefore the use of IGF-IEc have
been prohibited according to the regulations of the World Anti-Doping Agency (WADA)
since 2005 [6].
In 2014 a formerly unreported recombinant and non-natural protein was identified and
characterized by state-of-the-art analytical approaches [6]. The molecular sequence of this
unknown substance is closely related to human IGF-IEc: the C-terminus has been found to be
modified compared to human IGF-IEc by replacing the terminal lysine and arginine residues
by a histidine (See Fig 1). Therefore this unknown substance has been denoted full-length
MGF and can be considered as an analog of human IGF-IEc.
The insulin-IGF system includes at least four receptors: the IGF-I receptor (IGF-IR), the
IGF-II receptor, the insulin receptor-A (IR-A) and the insulin receptor-B (IR-B). Both the
IGF-IR and the IRs belong to the family of ligand-activated receptor kinases. Binding of a
ligand to the extra-cellular alpha subunit of the IGF-IR or the IRs induces the receptors to
undergo a conformational change, which enables autophosphorylation of the intrinsic tyrosine
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kinase domains of the beta-subunits of the IGF-IR and the IRs, respectively. Several lines of evi-
dence indicate that autophosphorylation of the IGF-IR and IRs initiates the majority of the bio-
logical effects mediated by IGF-I and insulin.
Kinase Receptor Activation (KIRA) bioassays make use of cell lines stably transfected with
receptors and quantify ligand bioactivity by measuring ligand-induced receptor tyrosine kinase
activation in terms of receptor-phosphorylation [7]. In our laboratory we have established
KIRA bioassays specific for the human IGF-IR, human IR-A and human IR-B, respectively [8,
9]. This allows us to specifically compare the activity of full-length MGF with IGF-I and insulin
with respect to their ability to activate the IGF-IR, IR-A and IR-B. In addition, we tested
whether stimulating activity of full-length MGF on the IGF-IR, IR-A and IR-B differs in action
from human MGF and its stabilized analog Goldspink -MGF [3, 10].
Materials and Methods
Materials
The human embryonic kidney cell-line (HEK) Flip-in™-293 was obtained from Invitrogen life
technologies (Breda, The Netherlands). Plasmids (pNTK-2) containing a cDNA insert of the
human IR-B(pNTK2-IR-B) or IR-A (pNTK2-IR-A) were kindly provided by Axel Ullrich
(Martinsried, Germany). The HEK IGF-IR cell-line was a kind gift from P. de Meyts (Gentofte,
Denmark). Dulbecco's Modified Eagles Medium (DMEM: gluc+, L-Glutamin +,Pyr+), Penicil-
lin/ Streptomycin, Hygromycine, Geneticin, Fugene1 transfection reagens and FBS were
obtained from Invitrogen life technologies (Breda, The Netherlands). Human Serum Albumin
Fig 1. Sequence, number of amino acids andmolecular weight of human IGF-I, three human pro-IGF-I isoforms, full-length MGF, HumanMGF,
Goldspink-MGF and Long R3-IGF-I (modified from Thevis et al. (6)).
doi:10.1371/journal.pone.0150453.g001
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(HSA), (Octalbine1) was obtained from Octapharma (Lachen, Switzerland). Culture plates
(flat-bottomed 48 wells) were obtained from Corning Costar (Schiphol, The Netherlands).
Microtiter 96-wells plates were purchased from Perkin Elmer-life sciences (Groningen, The
Netherlands). Antibody coating buffer contained 15mM sodium carbonate and 35mM sodium
hydrogen carbonate (pH 9.6). Blocking solution contained 40mM phosphate, 0.005% (wt./vol)
NaN3, 0.6% (wt./vol) NaCl, and 0.2% (wt./vol) Titriplex V (EDTA), and 1% (wt./vol) HSA (pH
8.0). Krebs Ringer bicarbonate buffer was adjusted to pH 7.4 by CO2 and supplemented with
0.1% (wt./vol) HSA. Lysis buffer contained 50 mMHEPES, 137 mMNaCl, 10 mM NaP2O7,
10mM NaF, 0.1mMMgCl2.6H20, 1 mM CaCl2.2H20, 0.1% NP-40, 10% (vol/vol) Glycerol
(pH 7.4) (before use, 1 tablet of EDTA free protease inhibitor and 0.5 ml 200 mM sodium
orthovanadate 14H20 was added to 50mL of lysis buffer). MAI1 and MAD1, monoclonal anti-
bodies directed against the extracellular domain of the human IR and human IGF-IR, respec-
tively, were obtained from Novozymes-Gropep (Adelaide, Australia). Phospho-Tyrosine
Biotinylated Antibodies were obtained from R&D Systems Inc (BAM 1676; R&D Systems
Europe Ltd, Abingdon, U.K.); streptavidin-labeled europium (DELFIA Eu-N1) was obtained
from Perkin Elmer-life sciences (Groningen, The Netherlands). DELFIA assay reagents (assay
buffer, wash buffer and enhancement solution) and a time-resolved fluorometer (Victor2 mul-
tilabel counter) were also purchased from Perkin Elmer-life sciences.
Peptides
An aliquot of an unknown substance offered to athletes and/or their managers in 2014, was
obtained and characterized by state-of-the-art analytical approaches including gel electropho-
retic and mass spectrometric (top-down and bottom-up) sequencing approaches as reported
elsewhere [6]. This substance turned out to have a monoisotopic molecular mass of 12264.9 Da
and to be a protein, lacking the signal- and propeptide moiety, with a molecular sequence
closely related to human IGF-IEc [6]: compared to human IGF-IEc the C-terminus has been
modified by replacing the terminal lysine and arginine residues by a histidine residue (See Fig
1). After confirmation of its amino acid sequence, it has been denoted full-length MGF and can
be considered as an analog of human IGF-IEc (Fig 1). A 1 mg lyophilisate aliquot of full-length
MGF was dissolved in 1 mL of deionized water in a low-bind Eppendorf tube to obtain the
stock solution, as previously described by Thevis et al.[6].
For the present study human MGF (Cat no 033–35) and its stabilized analog Goldspink-
MGF (Cat no 033–34) were obtained from Phoenix Pharmaceuticals Inc., (Burlingame, USA).
Noteworthy the use of the termMGF has been ambiguous in the literature in the literature, i.e.
referring to IGF-1Eb/Ec mRNA, pro-IGF-1Eb, as well as the (synthetic) MGF peptide [6]. It
has lately been recommended to use the name MGF solely for synthetic analogues [2]. Human
recombinant IGF-I was obtained from Austral Biologicals (San Ramon, USA). Recombinant
human Long-R3 IGF-I (Cat no 143045-27-6) was obtained from Sigma-Aldrich (Saint Louis,
USA) (Fig 1). Human insulin (HI (insuman1) was obtained from Sanofi-Aventis (Frankfurt
amMain, Germany).
The IGF-IR, IR-A, and IR-B KIRA assays
The IGF-IR stimulating activity of full-length MGF, human MGF and Goldspink-MGF, and
long-R3 IGF-I, respectively, were compared to IGF-I by using in-house KIRA bioassay specific
for the IGF-IR. The IR-stimulating activity of full-length MGF, human MGF and Goldspink-
MGF, respectively, were compared to HI by using in-house KIRA bioassays specific for the
IR-A or the IR-B. The IGF-IR, IR-A and IR-B KIRA bioassays have been previously described
and are based on a similar principle [8, 9, 11]. All three assays use human embryonic renal cells
IGF-I Receptor Stimulating Activity of Full-Length MGF
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were stably transfected with either cDNA of the human IGF-IR gene (HEK IGF-IR) or with
cDNA of the human IR-A or human IR-B gene (HEK IR-A or IR-B). Assays were performed
in 48 well plates. After 48 h of culture HEK IGF-IR cells were stimulated for 15min at 37°C
with an equimolar dose titration ranging from 0.0625 to 1000 moll/L of full-length MGF,
human MGF and Goldspink-MGF or human recombinant IGF-I, respectively. After 48 h of
culture HEK IR-A and HEK IR-B cells were stimulated for 10 min at 37°C with an equimolar
dose titration ranging from 0.03125 nmol/L to 500 nmol/L of full-length MGF, human MGF
and Goldspink-MGF or HI, respectively. After stimulation cells were lysed. Crude lysates were
transferred to a sandwich assay. Capture antibodies MAD1 and MAI1 were used in a concen-
tration of 5.0 μg/mL and 2.5 μg/mL, respectively. A biotinylated antiphosphotyrosine monoclo-
nal antibody was used in a concentration of 0.2 μg/mL as detection antibody in conjunction
with streptavidin-labeled europium in a concentration of 50 pmol/L. After a wash step, concen-
trations were read in a time-resolved fluorometer. A reference dose-titration-curve of human
recombinant IGF-I (IGF-I KIRA) or human recombinant insulin (IR-A KIRA and IR-B KIRA)
was implemented on all plates to ensure assay performance. All measurements were done in
duplicate. The inter- and intra-assay CVs were<15% [12].
Statistical Analysis
Data were analysed using GraphPad software (Prism 5, London, United Kingdom). The mea-
surements of IGF-IR stimulating activity or IR-stimulating activity are presented as
means ± SEM and signal-to-noise ratios. Noise was defined as signal after stimulation with vehi-
cle and so signal-to-noise ratios were calculated by using the formula: absolute counts after stim-
ulation with a ligand, divided by absolute vehicle counts. Differences in IGF-IR, IR-A or IR-B
stimulating activity between two ligands were calculated using repeated TwoWay ANOVA
with Bonferroni correction. Estimation of EC50 values were calculated using a non-linear
regression model for a sigmoidal dose-response curve with a variable slope. Values are presented
as means with 95% CI. A two-sided p-value of<0.05 was considered statistically significant.
Results
A] IGF-IR stimulatory activity
1. Comparison of full-length MGF vs. recombinant human IGF-I. At equimolar con-
centrations in the lower range full-length MGF generated significantly less IGF-IR stimulatory
activity than recombinant human IGF-I (Fig 2A). The IGF-IR stimulatory activity of full-
length MGF started at a concentration of 1.00 nmol/L compared to 0.0625 nmol/L for recombi-
nant IGF-I (Fig 2A). The dose response curve of full-length MGF showed a bell-shaped curve
(Fig 2A). Maximal stimulatory activity of the IGF-IR generated by full-length MGF (89-fold
stimulation) was similar to that induced by recombinant human IGF-I (77-fold stimulation)
and was achieved at 31.25 nmol/L for full-length MGF compared to 7.81 nmol/L for recombi-
nant human IGF-I (Fig 2A). The EC50 values of full-length MGF and recombinant human
IGF-I for the IGF-IR were 7.83 nmol/L (95% CI: 4.87–12.58) and 0.86 nmol/L (95% CI 0.69–
1.07) respectively.
2. Comparison Human MGF and Goldspink-MGF vs. recombinant human IGF-I. At
concentrations0.25 nmol/L IGF-IR stimulatory activity was significantly different between
human MGF and recombinant human IGF-I (P<0.001). In contrast to recombinant human
IGF-I, human MGF did not stimulate the IGF-IR at all concentrations tested (Fig 2B). Simi-
larly, at concentrations0.25 nmol/L IGF-IR stimulatory activity was significantly different
between Goldspink-MGF and recombinant human IGF-I (p<0.001). In contrast to
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recombinant human IGF-I, Goldspink-MGF did not stimulate the IGF-IR at any concentra-
tions tested (Fig 2C).
3. Comparison of Recombinant human Long- R3 IGF-I vs. recombinant human IGF-I
The dose response curve of recombinant human long R3 IGF showed a bell-shaped curve (Fig
2D). The IGF-IR stimulatory activity of recombinant human Long-R3 IGF-I started at a con-
centration of 0.125 nmol/L compared to 0.0625 nmol/L for recombinant IGF-I. At equimolar
concentrations in the lower range and the higher range human long R3 IGF-I generated signifi-
cantly less IGF-IR stimulatory activity than recombinant human IGF-I (Fig 2D). However,
maximal stimulatory activity of the IGF-IR generated by Long-R3 IGF (68-fold) was similar to
that induced by recombinant human IGF-I (82-fold stimulation) (Fig 2D). Maximal IGF-IR
stimulation was achieved at 3.91 nmol/L for recombinant human IGF-I and at 7.81 nmol/L for
recombinant human Long- R3 IGF-I (Fig 2D). The EC50 value of recombinant human recom-
binant IGF- and Long-R3 IGF-I for the IGF-IR were 0.94 nmol/L (95% CI 0.74–1.19) and 1.92
nmol/L (95% CI 1.52–2.43), respectively.
B] IR-A stimulatory activity
1. Comparison of full-length MGF vs. recombinant human insulin. The IR-A stimula-
tory activity of full-length MGF started at a concentration of 4.00 nmol/L compared to 0.0625
nmol/L for recombinant human insulin (Fig 3A). In the range between 0.98 and 31.25 nmol/L
Fig 2. Stimulatory activity of the insulin-like growth factor-I receptor (IGF-IR). A: Comparison of full-length MGF (red points and line) and insulin-like
growth factor-I (IGF-I) (green points and line). B:Comparison of Human MGF (red points and line) and insulin-like growth factor-I (IGF-I) (green points and
line).C: Comparison of Goldspink-MGF (red points and line) and insulin-like growth factor-I (IGF-I) (green points and line).D: Comparison of Long R3 IGF
(red points and line) and insulin-like growth factor-I (IGF-I) (green points and line). Dose-response curves ranged from 0.0625 to 1000 nmol/L. For bioactivity
measurements means ± SEM and signal-to-noise ratios are presented.A-C: Each point represents the mean value ± SEM of at least three independent
experiments. D: Each point represents the mean value ± SEM of at least two independent experiments. P = P-value when comparing overall differences in
fold stimulation between two ligands.
doi:10.1371/journal.pone.0150453.g002
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IR-A stimulatory activity for full-length MGF was significantly lower than that of recombinant
human insulin. However, maximal stimulatory activity of the IR-A generated by ‘full-length
MGF’ (235-fold stimulation) was similar to that generated by recombinant human insulin
(193-fold stimulation) and was achieved at 500.0 nmol/L for full-length MGF and at 62.50
nmol/L for recombinant human insulin (Fig 3A). The EC50 values of full-length MGF and
recombinant human insulin for the IR-A receptor were 73.11 nmol/L (42.87–124.69) and 1.13
nmol/L (95% CI 0.69–1.84), respectively.
2. Comparison of Human MGF and Goldspink-MGF vs. recombinant human insulin.
At concentrations0.50 nmol/L IR-A stimulatory activity was statistically different between
humanMGF and recombinant human insulin (Fig 3B). In contrast to recombinant human
insulin, humanMGF did not stimulate the IR-A at all concentrations tested (Fig 3B). At concen-
trations0.50 nmol/L IR-A stimulatory activity was statistically different between Goldspink-
MGF and recombinant human insulin (P<0.001) (Fig 3C). In contrast to recombinant human
insulin, Goldspink-MGF did not stimulate the IR-A at all concentrations tested (Fig 3C).
C] IR-B stimulatory activity
1. Comparison of full-length MGF vs. recombinant human insulin. The IR-B stimula-
tory activity of full-length MGF started at a concentration of 0.98 nmol/L compared to 0.0625
Fig 3. Stimulatory activity of the insulin receptor-A (IR-A). A: Comparison of full-length MGF (red points and line) and insulin (green points and line). B:
Comparison of HumanMGF (red points and line) and insulin) (green points and line). C:Comparison of Goldspink-MGF (red points and line) and insulin
(green points and line). Dose-response curves ranged from 0.03125 nmol/L to 500 nmol/L. For bioactivity measurements means ± SEM and signal-to-noise
ratios are presented.A-C: Each point represents the mean value ± SEM of at least three independent experiments. P = P-value when comparing overall
differences in fold stimulation between two ligands.
doi:10.1371/journal.pone.0150453.g003
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nmol/L for recombinant human insulin (Fig 4A). Full-length MGF at equimolar concentra-
tions in the lower concentration range generated less IR-B stimulatory activity than recombi-
nant human insulin, but at equimolar concentrations in the upper concentration range had
significantly higher IR-B stimulatory activity than recombinant human insulin (Fig 4A). Maxi-
mal IR-B stimulatory activity of full-length MGF was considerably higher (292-fold) than that
induced by recombinant human insulin (98-fold) and this was achieved at the maximum dose
tested of 500.0 nmol/L for both full-length MGF and recombinant human insulin (Fig 4A).
The EC50 values of full-length MGF and recombinant human insulin for the IR-B receptor
were 35.91 nmol/L (95% 17.52–70.33) and 1.28 nmol/L (95% CI 0.64–2.57), respectively.
2. Comparison of Human MGF and Goldspink-MGF vs. recombinant human insulin.
At concentrations0.50 nmol/L IR-B stimulatory activity was statistically different between
humanMGF and recombinant human insulin (P<0.001) (Fig 4B). In contrast to recombinant
human insulin, humanMGF did not stimulate the IR-B at all concentrations tested (Fig 4B). Sim-
ilarly, at concentrations0.50 nmol/L IR-B stimulatory activity was statistically different between
Goldspink-MGF and recombinant human insulin (P<0.001) (Fig 4C). In contrast to recombinant
human insulin, Goldspink- MGF did not stimulate the IR-B at all concentrations tested (Fig 4C).
Discussion
When we tested in vitro potency with our in house IGF-IR KIRA assay, full -length MGF at
equimolar concentrations in the lower ranges generated less IGF-IR stimulatory activity than
Fig 4. Stimulatory activity of the insulin receptor-B (IR-B). A: Comparison of full-length MGF (red points and line) and insulin (green points and line).B:
Comparison of HumanMGF (red points and line) and insulin) (green points and line). C:Comparison of Goldspink-MGF (red points and line) and insulin
(green points and line). Dose-response curves ranged from 0.03125 nmol/L to 500 nmol/L. For bioactivity measurements means ± SEM and signal-to-noise
ratios are presented.A-C: Each point represents the mean value ± SEM of at least three independent experiments. P = P-value when comparing overall
differences in fold stimulation between two ligands.
doi:10.1371/journal.pone.0150453.g004
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recombinant human IGF-I, suggesting that the IGF-IR is less sensitive to full -length MGF
than to recombinant human IGF-I. However, despite a higher EC50 concentration, at high
equimolar concentrations full-length MGF showed a similar maximal potency to activate the
IGF-IR than IGF-I (Fig 2A).
The IGF-I KIRA assay measures a physiologically meaningful parameter: quantification of
the phosphorylated tyrosine residues within the ß-subunits of the IGF-IR. Phosphorylation of
the tyrosine residues of the ß-subunits of the IGF-IR initiates the majority, if not all of the bio-
logical effects mediated by the IGF-IR. On the other hand, the IGF-IR KIRA assay provides no
direct information about intracellular post-receptor effects. For example, we do not know
whether activation of the IGF-I receptor by full- length MGF results (like human IGF-I) in
more mitogenic as opposed to metabolic activity of the IGF-I receptor.
The molecular structure of full-length MGF shows considerable homology with IGF-1Ec,
which is one of three known IGF-I isoforms, that are naturally occurring in humans [6] (see also
Fig 1). The intact molecular weight of full-length MGF is 147, 2 Da lower than that of human
IGF-1Ec. This discrepancy in molecular weight is due to a slight structural difference between
both substances in molecular structure. Full- length MGF is one amino acid shorter and contains
a histidine residue at the carboxy-terminus instead of arginine and lysine [6]. Full-length MGF
can thus be considered as a pro-IGF-I with slight modifications. Our finding that full-length
MGF directly stimulates the IGF-IR, challenges the current concept that the E-peptide of pro-
IGF-I has to be cleaved off from the IGF-I molecule to become biologically active [13, 14].
The residence time in vivo of a given glycoprotein is often dependent on its glycosylation
status [15]. On the other hand, a lack of glycosylation may also reduce the ability of a ligand to
activate a receptor [1]. Thus, the glycosylation state of MGF may be an important factor and it
has been suggested that glycosylated MGF directly associates with the extracellular matrix
(ECM), thereby serving as an alternate additional reservoir of this growth factor: as such glyco-
sylation may attribute to a delayed clearance, while cleavage of the entire E-peptide by extracel-
lular proteases could release active mature IGF-I for receptor binding when needed [1].
However, the full-length MGF molecule we studied appeared to be a pure peptide structure
which is not glycosylated [6]. It also does not show any additional signals or indications for gly-
can residues [6]. Our results support previous observations that IGF-IR stimulatory activity of
mature IGF-I and non-glycosylated MGF are similar [1].
The stimulatory effects on the IGF-IR in the KIRA assay occurred at relatively high molar
concentrations of full-length MGF. However, at present no information is available about the in
vivo concentrations of MGF at the IGF-I receptor site. In the physiological states in the human
body MGF probably does not enter the bloodstream in any significant quantity, but remains in
the muscular compartment [4]. It has been suggested that the E-peptide may prevent release of
MGF into the bloodstream by tethering MGF to the site of synthesis and/or administration [16].
This would help to increase the local actions of MGF [4]. In this context, the recently reported
findings for polyethylene glycol (PEG)ylated IGF-I are very interesting: it has been demon-
strated that a single intramuscular injection of PEG-IGF-I was more efficacious than systemic
administration of PEG-IGF-I or a single intramuscular injection of recombinant human IGF-I
for hastening early muscle fiber regeneration and improving muscle function after injury [17].
This latter effect was attributed to a delayed clearance of PEG-IGF-I after intramuscular injec-
tion and suggests that molecular modifications near the C terminus of the IGF-I molecule are
very important to increase the actions of IGF-I at the tissue level [1, 17]. Whether full-length
MGF in this respect resembles PEG-IGF-I is not clear at present and should be studied.
It would be very interesting to determine whether full-length MGF and IGF-I differ in their
kinetics of IGF-IR activation. However, due to a limited availability of full-length MGF, we
could not directly assess IGF-IR activation kinetics of full-length MGF to compare it with IGF-I.
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It is well established that Human MGF and Goldspink-MGF are synthetic IGF-I E peptide
analogues corresponding to the last 24 amino acids of the E domain of the IGF-IEc isoform [6].
It has been suggested that these E peptides may function as independent growth factors [18].
In our hands, human MGF and Goldspink-MGF in the IGF-IR KIRA assay induced no stimu-
latory activity of the IGF-IR. In line with our findings, it has been found that the E-peptides do
not directly induce IGF-IR phosphorylation [19, 20]. Although in a rodent model, exposure to
E- peptides has been shown to increase myoblast proliferation and migration, many of these
effects were apparent even when IGF-IR was blocked via a neutralizing antibody, indicating
that these E-peptide actions were independent of IGF-IR signaling [19].
Long-R3 IGF-I is derived from native IGF-I by replacing the third amino acid in the mature
peptide, glutamine, with arginine [21]. This substitution gives Long-R3 IGF-I a>100-fold
reduced affinity for IGFBPs without compromising IGF-IR affinity [22]. At both low and high
equimolar concentrations, Long -R3 IGF-I was less potent to activate of the IGF-IR than
recombinant human IGF-I. However, maximal stimulatory activity of the IGF-IR generated by
Long-R3 IGF (68-fold) was similar to that induced by recombinant human IGF-I and the dose-
response curve of Long-R3 IGF-I was bell-shaped [21]. Despite our findings, Long-R3 IGF-I
may still act in vivo as a more potent growth factor than native IGF-I, due to its considerably
reduced affinities for the IGFBPs in plasma [23, 24]. It has been reported that Long-R3 IGF-I
demonstrated an increased bioavailability and potency at the target tissues due to its faster
clearance from blood into the target tissues in comparison to native IGF-I [23, 24].
The structures of the IRs and the IGF-IR resemble each other to such an extent that insulin
and IGFs can interact with the respective other receptor, although with quite different affinities
and actions [25]. This may be also true for IGF-I isoforms. Since full-length MGF shows con-
siderable structural similarities with mature IGF-I, we also investigated whether full-length
MGF may stimulate the IRs and observed that full -length MGF also stimulated the IR-A and
IR-B. The IR-A and the IR-B stimulatory activity started at higher concentrations of full-length
MGF compared to those inducing IGF-IR stimulatory activity. In addition, at equimolar con-
centrations in the lower range, sensitivity of the IRs to stimulation with full-length MGF was
less compared to human insulin. However, it is important to note that at high equimolar con-
centrations similar maximal IR-A stimulating effects were found for full -length MGF and
human insulin, however, maximal stimulatory activity achieved for the IR-B was stronger after
full- length MGF than by equimolar doses of human insulin. In contrast to the above described
effects for the IGF-IR, the dose-response curves of full-length MGF for both IRs showed no
peak/plateau at the concentrations tested and the stimulation of the IRs progressively increased
with higher concentrations of full-length MGF. In addition, for both IRs the maximal stimula-
tory activity induced by full-length MGF apparently was not reached at the highest concentra-
tion of full length MGF tested (Figs 3A and 4A).
Although a limitation of this study may be that affinities of the IGF-IR and the IRs for full-
length MGF were not measured, biological responses do not parallel ligand binding and, there-
fore, are not exclusively determined by the affinity of a particular receptor for that ligand [26].
In addition, the magnitude of a cellular response to a ligand is determined by summation of all
the signals generated by each of the occupied receptors, and therefore is related to number of
receptors that are activated rather than the fraction of the total receptor pool that is bound by
the ligand [26]. With the KIRA assays the total amount of autophosphorylation of tyrosine res-
idues of a particular receptor (IGF-IR, IR-A and IR-B) is measured which initiates most if not
all of the biological effects of these receptors. Therefore, the KIRA assays produce physiologi-
cally more relevant information than the assessment of the affinities of the IGF-IR and the IRs
As previously discussed for the IGF-IR, both IR KIRA assays do not produce information
about intracellular post-receptor events. At present we do not know which metabolic and
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mitogenic responses are induced by activation of the IRs by full-length MGF. While it is appar-
ent from our study that full-length MGF induces a phosphorylation pattern of the IR-B, which
is significantly different from that of insulin, the potential consequences of this different phos-
phorylation pattern for the human body in vivo are not yet obvious.
At present it is not clear to what extent our in vitro findings about full length MGF can be
translated into biological responses of cells in vivo and whether this substance may improve
skeletal muscle function and/or hypertrophy. New studies in animals should be initiated to
gather in vivo information about efficacy, toxicity and pharmacokinetics of full-length MGF.
In conclusion, full-length MGF in vitro at equimolar concentrations in the lower range
demonstrated lower activation of the IGF-IR than IGF-I. However, despite a higher EC50 con-
centration, at equimolar concentrations in the higher ranges maximal IGF-IR stimulatory
activity achieved by full-length MGF was similar (90-fold) to that after recombinant human
IGF-I (82-fold). No IGF-IR stimulatory activity was induced by human MGF and Goldspink-
MGF, respectively.
At high equimolar concentrations similar maximal levels of IR-A stimulating effects were
observed for full-length MGF and human insulin, but maximal stimulatory activity achieved
for the IR-B was stronger after full- length MGF than after adding equimolar doses of human
insulin. Both the IRs showed no clear peak/plateau in stimulatory activity and the stimulatory
activity of the IRs progressively increased with higher concentrations of full-length MGF.
Further research is needed to better understand the actions of full-length MGF in vivo and
to place our in vitro findings into the context of the actions of full-length MGF in vivo.
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